BTIG Research Forecasts Strong Price Appreciation for GeneDx (NASDAQ:WGS) Stock

GeneDx (NASDAQ:WGS) had its target price boosted by equities research analysts at BTIG Research from $140.00 to $165.00 in a report released on Wednesday, Marketbeat reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target would suggest a potential upside of 25.48% from the company’s previous close.

A number of other equities analysts have also weighed in on WGS. Piper Sandler increased their price target on GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, September 11th. Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 2nd. Wall Street Zen upgraded GeneDx from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group set a $155.00 price target on shares of GeneDx and gave the stock a “buy” rating in a research report on Monday, October 20th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.22.

GeneDx Trading Down 0.2%

NASDAQ:WGS opened at $131.50 on Wednesday. The company has a quick ratio of 2.70, a current ratio of 2.71 and a debt-to-equity ratio of 0.18. GeneDx has a 1-year low of $55.17 and a 1-year high of $146.00. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of 1,461.11 and a beta of 1.98. The stock has a fifty day simple moving average of $124.10 and a 200 day simple moving average of $98.75.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.21. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The business had revenue of $116.74 million during the quarter, compared to analyst estimates of $104.33 million. GeneDx has set its FY 2025 guidance at EPS. Sell-side analysts forecast that GeneDx will post 0.97 earnings per share for the current year.

Insider Buying and Selling

In other GeneDx news, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total value of $1,275,556.47. Following the transaction, the chief executive officer directly owned 14,578 shares of the company’s stock, valued at $1,770,789.66. The trade was a 41.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jason Ryan sold 38,072 shares of the business’s stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $127.30, for a total value of $4,846,565.60. Following the sale, the director owned 103,284 shares in the company, valued at approximately $13,148,053.20. This represents a 26.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 553,829 shares of company stock valued at $67,221,616 in the last quarter. Company insiders own 29.60% of the company’s stock.

Institutional Trading of GeneDx

Several institutional investors have recently bought and sold shares of WGS. GAMMA Investing LLC boosted its stake in GeneDx by 151.7% in the 1st quarter. GAMMA Investing LLC now owns 438 shares of the company’s stock valued at $39,000 after buying an additional 264 shares in the last quarter. US Bancorp DE lifted its stake in shares of GeneDx by 3,223.5% during the first quarter. US Bancorp DE now owns 565 shares of the company’s stock valued at $50,000 after acquiring an additional 548 shares during the period. AlphaQuest LLC lifted its stake in shares of GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock valued at $70,000 after acquiring an additional 594 shares during the period. KBC Group NV acquired a new position in shares of GeneDx during the first quarter valued at $81,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of GeneDx during the first quarter valued at $132,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.